Table 4 Relationship between CD47 and clinicopathological and genomic characteristics of EOC

FIGO stage

75

-

-

 < 0.001

 I/II

23

19 (82.6)

4 (17.4)

-

 III/IV

52

9 (17.3)

43 (82.7)

-

Preoperative serum CA125

75

-

-

0.002

 < 500 U/mL

42

22 (52.4)

20 (47.6)

-

 ≥ 500 U/mL

33

6 (18.2)

27 (81.8)

-

Preoperative serum HE4

69^a

-

-

0.013

 Normal

17

11 (64.7)

6 (35.3)

-

 Increased

52

16 (30.8)

36 (69.2)

-

Multidisciplinary surgeries^b

75

-

-

 < 0.001

 No

33

26 (78.8)

7 (21.2)

-

 Yes

42

2 (4.8)

40 (95.2)

-

Ascites

75

-

-

0.003^▲

0.010^▲▲

 None

18

12 (66.7)

6 (33.3)

-

 < 1000 ml

36

13 (36.1)

23 (63.9)

-

 ≥ 1000 ml

21

3 (14.3)

18 (85.7)

-

Lymph-node metastasis

75

-

-

 < 0.001

 Negative

37

25 (67.6)

12 (32.4)

-

 Positive

38

3 (7.9)

35 (92.1)

-

Ki-67 index

75

-

-

0.002

 Negative

34

19 (55.9)

15 (44.1)

-

 Positive

41

9 (22.0)

32 (78.0)

-

PD-L1 expression

75

-

-

0.014

 Negative

48

23 (47.9)

25 (52.1)

-

 Positive

27

5 (18.5)

22 (81.5)

-

Residual lesion

75

-

-

0.753

 Optimal

60

23(38.3)

37(61.7)

-

 Suboptimal

15

5(33.3)

10(66.7)

-

MSI status

75

-

-

0.407

 MSS/MSS-L

70

27 (38.6)

43 (61.4)

-

 MSS-H

5

1 (20.0)

4 (80.0)

-

HRD status

55^†

-

-

0.003

 Negative

20

11 (55.0)

9 (45.0)

-

 Positive

35

6 (17.1)

29 (82.9)

-

BRCA mutation status

75

-

-

0.021

 Wild type

52

24 (46.2)

28 (53.8)

-

 Pathogenic mutation

23

4 (17.4)

19 (82.6)

-

TP53 mutation status

75

-

-

0.001

 Wild type

21

14 (66.7)

7 (33.3)

-

 Pathogenic mutation

54

14 (25.9)

40 (74.1)

-

Response to frontline therapy

75

-

-

0.126

 CR^†

69

28 (40.6)

41 (59.4)

-

 PR or PD^††

6

0 (0.0)

6 (100.0)

-

Platinum status

75

-

-

0.002

 Sensitive

62

28 (45.2)

34 (54.8)

-

 Resistant

13

0 (0.0)

13 (100.0)

-